The genes expressed - turned on, off, up or down - in any given cell determine its type and function. When the wrong genes are expressed at the wrong time or in the wrong amounts, it can lead to disease.
At Syros, we have identified cancer patients with aberrant expression of genes that can be targeted with new therapies. We are focused on applying this approach to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded current targeted approaches, we are advancing our late-stage clinical pipeline to provide new treatment options. We invite you to learn more about Syros and our mission to improve the lives of cancer patients.
Connect With Us